Abstract
Since May 2022 over 20.000 human monkeypox virus (hMPXV) cases have been reported from 29 EU/EEA countries, predominantly among men who have sex with men. With over 1200 cases, and a crude notification rate of 70.7 per million population, the Netherlands was in the top 5 European countries most affected. The first national case was reported from May 10th, yet potential prior transmission remains unknown. Insight into prolonged undetected transmission can help to understand the current outbreak dynamics and aid future public health interventions. We therefor performed a retrospective study to elucidate whether undetected transmission of hMPXV occurred prior to the first reported cases in Amsterdam and Rotterdam. In 401 anorectal- and ulcer samples from visitors of the Centers for Sexual Health of Amsterdam and Rotterdam dating back to February 14th, we identified 2 new cases, the earliest from the first week of May (week 18), 2022. This coincides with the first cases reported in the United Kingdom, Spain and Portugal. We found no evidence of widespread hMPXV transmission in Dutch sexual networks of MSM prior to May 2022. Likely, the hMPXV outbreak expanded across Europe within a short period in the spring of 2022 in an international highly intertwined network of sexually active MSM.
Ethical statement The Amsterdam University Medical Centre Ethical committee approved the study and deemed a full review not necessary according to the Medical Research Involving Human Subjects Act (reference letter: W22_257 # 22.313, dd July 14, 2022). Samples included from Rotterdam were required to be collected more than 3 weeks prior to the analysis (i.e. the duration of quarantine in case of a positive result) as they were deemed to be of no consequence for the index or his/her contacts. All samples and collected data were fully de-identified before sample analysis assuring anonymity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Amsterdam University Medical Centre Ethical committee approved the study and deemed a full review not necessary according to the Medical Research Involving Human Subjects Act (reference letter: W22_257 # 22.313, dd July 14, 2022). Samples included from Rotterdam were required to be collected more than 3 weeks prior to the analysis (i.e. the duration of quarantine in case of a positive result) as they were deemed to be of no consequence for the index or his/her contacts. All samples and collected data were fully de-identified before sample analysis assuring anonymity.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
